ENDOCRINE ABNORMALITIES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Piotr Kuczera, Marcin Adamczak, Andrzej Wiecek

Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland

Corresponding Author: Prof. dr hab. med. Andrzej Wiecek, FRCP (Edin), FERA, Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Francuska Str. 20/24, 40-027 Katowice, Poland; Tel: +48-322552695, Fax: +48-322553726; E-mail: awiecek@sum.edu.pl

Abstract
In patients with chronic kidney disease the alterations of the endocrine system may arise from several causes. The kidney is the site of degradation as well as synthesis of many different hormones. Moreover, a number of concomitant pathological conditions such as inflammation, metabolic acidosis and malnutrition may participate in the pathogenesis of endocrine abnormalities in this group of patients. The most pronounced endocrine abnormalities in patients with chronic kidney disease are the deficiencies of: calcitriol, testosterone, insulin-like growth factor and, erythropoietin (EPO). Additionally accumulation of several hormones, such as: prolactin, growth hormone and insulin frequently also occur. The clinical consequences of the abovementioned endocrine abnormalities are among others: anemia, infertility and bone diseases.

Key words: Chronic kidney disease, Endocrine abnormalities, Erythropoietin

Introduction
Endocrine abnormalities in patients with chronic kidney disease (CKD) and in patients receiving renal replacement treatment (RRT) may arise from a number of different causes, which are briefly summarized in Table 1.

The kidneys are complex organs in which the synthesis and degradation of different hormones takes place. Moreover, several concomitant conditions e.g.: inflammation, metabolic acidosis and malnutrition can participate in the pathogenesis of many alterations of the endocrine system.
The clinicians nowadays have a possibility to assess plasma concentration of several different hormones, all of which may, or may not be abnormal. However, many of these measurements are of limited value in CKD and RRT patients. Estimation of plasma concentrations of many hormones has been shown not to provide a proper assessment of the hormonal status adequacy (hormone concentrations may be inadequate in the context of stimulating or suppressing signals, the test can detect inactive hormone isoforms, also the target organs’ response may be aggravated or blunted). Therefore it seems necessary to interpret plasma hormone concentrations along with the underlying clinical context (e.g.: parathyroid hormone (PTH) concentration in relation to the ionized calcium concentration, or insulin concentration in relation to glucose concentration).

Table 1

*The etiology of selected endocrine abnormalities in chronic kidney disease*

<table>
<thead>
<tr>
<th>Type of defect</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abnormalities of hormone catabolism</strong></td>
<td>Insulin, PTH, leptin, adiponectin, gastrin</td>
</tr>
<tr>
<td>Decreased metabolic clearance</td>
<td></td>
</tr>
<tr>
<td><strong>Abnormalities of hormone production</strong></td>
<td>testosterone, estrogens</td>
</tr>
<tr>
<td>Reduced hormone production in endocrine organs</td>
<td>1,25(OH)₂D₃, erythropoietin</td>
</tr>
<tr>
<td>Reactive hypersecretion of hormone to reestablish homeostasis</td>
<td>PTH, FGF 23, erythropoietin</td>
</tr>
<tr>
<td>Inappropriate hypersecretion due to disturbed feedback</td>
<td>ACTH, LH, prolactin</td>
</tr>
<tr>
<td>Abnormal secretion pattern (pulsatility; circadian rhythm)</td>
<td>GH, LH</td>
</tr>
<tr>
<td><strong>Abnormalities of hormone activity</strong></td>
<td></td>
</tr>
<tr>
<td>Increased isoforms with potentially less bioactivity (because of posttranscriptional modifications)</td>
<td>LH</td>
</tr>
<tr>
<td>Increased serum hormone binding proteins concentration resulting in the reduced availability of free hormone</td>
<td>IGF</td>
</tr>
<tr>
<td>Decreased serum hormone binding proteins concentration resulting in the increased availability of free hormone</td>
<td>leptin</td>
</tr>
<tr>
<td>Changed receptor quantity and/or structure</td>
<td>vitamin D receptor</td>
</tr>
<tr>
<td>Altered postreceptor cellular signaling</td>
<td>insulin, GH</td>
</tr>
<tr>
<td>Altered activation of prohormones</td>
<td>proinsulin, thyroxin (T₄)</td>
</tr>
</tbody>
</table>

PTH – parathyroid hormone; FGF 23 – fibroblast growth factor 23; ACTH – adrenocorticotropin; LH – luteinizing hormone; GH – growth hormone; IGF – insulin-like growth factor.

**Abnormalities in the secretion of erythropoietin**

In the adults kidneys are responsible of synthesis of approximately 85–90% of circulating erythropoietin (EPO), while the liver is the source of the remaining 10–15%.

The main stimulus for EPO synthesis in the peritubular cells of the renal cortex is the renal hypoxia, which may be caused by anemia or hypoxemia. Hypoxia stimulates Hypoxia Inducible Factor (HIF) synthesis, which is responsible for the activation of variety of genes, among others also the EPO gene.

Another factor stimulating the renal EPO production is angiotensin II. Conversely, proteins typically linked with inflammation (e.g. interleukin-1 – [IL-1] and tumor necrosis factor-α – [TNF-α]) inhibit EPO secretion. Recently it has been shown that also infectious factors such as CMV infection can reduce EPO synthesis in
the kidneys [a]. Plasma EPO concentration in anemic CKD and RRT patients is roughly similar as in nonanemic subjects with intact kidney function, but is inappropriately low in the context of the actual blood hemoglobin concentration. Moreover, in CKD patients erythropoietin resistance commonly occurs [1]. Anemia is the direct clinical consequence of EPO deficiency in CKD and RRT patients. Plasma EPO concentration assessment in CKD patients is not used in clinical practice. Decisions concerning treatment with erythropoiesis stimulating agents (ESAs) in CKD and RRT patients are based on the repeated measurement of the blood hemoglobin concentration as well as the patients’ clinical status but usually not on plasma EPO concentration.

Abnormalities in the vitamin D metabolites

In general population, low vitamin D status has been linked to increased occurrence of hypertension, cardiovascular diseases, metabolic syndrome, obesity, insulin resistance and albuminuria. The prevalence of 25-hydroxyvitamin D₃ deficiency increases with the progression of CKD and reaches 80% in patients with CKD stage 5. Additionally, in patients with nephrotic syndrome, the 25(OH)D₃ is excessively excreted with the urine. Moreover, in patients treated with peritoneal dialysis vitamin D is washed out with the peritoneal dialysis fluid. The supplementation with ergocalciferol in CKD patients is considered to be safe and is recommended in patients with serum 25(OH)D₃ concentration below 30 ng/ml.

25(OH)D₃ is further hydroxylated in the kidney, what results in the production of its active metabolite – 1,25(OH)₂D₃. With the decrease of GFR the decline in the activity of 1α-hydroxylase occurs. Moreover, the amount of 25(OH)D₃ delivered to the kidney (via receptor mediated mechanism involving megalin) decreases. Additionally, increased plasma concentration of Fibroblast Growth Factor 23 (FGF23) may directly inhibit the abovementioned hydroxylation and promote the synthesis of 24,25(OH)₂D₃, which seems to be metabolically inactive. Thus, in CKD stage 5 patients the plasma 1,25(OH)₂D₃ concentration is decreased. Moreover, a decrease in the density of 1,25(OH)₂D₃ receptors (VDR) in these CKD patients has been described. This leads to the target organ resistance to the 1,25(OH)₂D₃ in this group of patients.

Calcitriol deficiency in patients with CKD plays an important role in the development of secondary hyperparathyroidism, decreased absorption of calcium in the intestine, defective bone mineralization and skeletal resistance to the calcemic action of PTH as well as impaired longitudinal growth in children and myopathy. Some studies suggest that 1,25(OH)₂D₃ deficiency is responsible for the increase in the cardiovascular and general mortality in CKD patients. The results of the small interventional studies suggest that treatment with calcitriol or other VDR agonists may reduce the mortality among these patients. Recent studies showed that 1,25(OH)₂D₃ deficiency increases proteinuria in CKD patients and paricalcitol treatment seemed to ameliorate this pathology. Also, treatment with cinaclacel may be beneficial in this group of patients, as it decreases plasma FGF23 concentration, what may contribute to the lesser vitamin D₃ degradation in these patients and might decrease the cardiovascular risk.

Nevertheless, larger prospective studies are needed to further elucidate the abovementioned relations [2,b].

Abnormalities of the hypothalamic-pituitary-gonadal axis in male CKD patients

CKD is a prominent cause of many derangements of the hypothalamic-pituitary-gonadal axis in males (Table 2), the most of which affect directly the function of gonads.

### Table 1

<table>
<thead>
<tr>
<th>Hypothalamic-pituitary-gonadal axis disturbances in chronic kidney disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>FSH</td>
</tr>
<tr>
<td>LH</td>
</tr>
<tr>
<td>Prolactin</td>
</tr>
<tr>
<td>Estradiol</td>
</tr>
<tr>
<td>Progesterone</td>
</tr>
<tr>
<td>Testosterone</td>
</tr>
</tbody>
</table>

FSH – follicle-stimulating hormone; LH – luteinizing hormone; N – normal.

Follicle-stimulating hormone

In patients with CKD, serum concentrations of follicle stimulating hormone (FSH) may
be either elevated, or in the "upper normal" range. FSH is an important factor involved among others in spermatogenesis. It stimulates testicular growth and increases the synthesis of testosterone-binding globulin in the Sertoli cells. In CKD patients, spermatogenesis is usually impaired despite the elevated serum FSH concentrations, what may be caused by the testis resistance to FSH, or due to primary testicular dysfunction [3].

Luteinizing hormone
In patients with CKD, the lack of appropriate cyclic release of gonadotropin releasing hormone (GnRH) and the decrease amplitudes of the secretory bursts of GnRH by the hypothalamus occurs, what leads to a loss of normal pulsatile release of luteinizing hormone (LH) by the pituitary gland. Among the causes of altered cyclic release of GnRH hyperprolactinemia and high plasma GnRH and LH concentrations may be mentioned. These disturbances are caused mainly by reduced renal clearances of GnRH and LH [3].

In the majority of CKD patients, basal plasma LH concentrations are elevated, caused by the decreased catabolism and lack of GnRH inhibition by testosterone (due to lower plasma testosterone concentration in CKD).

Prolactin
In the majority of male hemodialysis patients serum prolactin (PRL) concentrations are elevated. Apart from the increased basal prolactin concentrations, also the daily rhythm of prolactin secretion is altered. Moreover, the sleep-induced secretory bursts of prolactin secretion are rarely observed, although episodic PRL secretion during the daytime occurs.

Probably both the decline of renal prolactin clearance and increased production rate (caused by the inadequate dopaminergic inhibition of prolactin release) contribute to hyperprolactinemia in patients with CKD [4]. Prolactin accumulation causes the inhibition of pulsatile secretion of GnRH as well as the decrement in the testosterone synthesis, which results in worsening of sexual functions and infertility. Interestingly, in some CKD patients, correction of the hyperprolactinemia by bromocriptine with concomitant improvement of sexual function has been described.

The association between hyperprolactinemia and negative cardiovascular outcome was also described in patients with CKD. This relation probably arises from the fact, that increased prolactin concentration may participate in the dysfunction of endothelium. In small clinical study a reduction of blood pressure and hypertrophy of left ventricle was found in patients with CKD after bromocriptine administration [4].

Testicular Hormones
In the majority of most hemodialysis males serum total and free testosterone concentrations are low, nonetheless the daily circadian rhythm of serum testosterone concentration fluctuations, with a peak at 4 to 8 am and nadir at 8 to 12 pm is usually maintained in CKD patients. It is not yet known whether the decreased serum testosterone concentration is caused by the impaired synthesis, aggravated catabolism, or a combination of both. Additionally, the response to stimulation with human gonadotropin is blunted and delayed.

Malnutrition also take part in the decreased serum concentrations of testosterone in CKD male patients. In CKD patients on a low-protein diet, essential amino acids and aminoacid ketoanalogues supplementation led to the increase of serum testosterone concentration [3, 5]. Moreover, the decreased serum concentration of androstenedione and dehydroepiandrosterone sulfate have been reported in male patients with CKD.

The deficiency of androgens in CKD males may be responsible of the changes in body composition. It leads to the increase of adipose tissue content, while the lean body mass (mainly mass of the muscles) is decreases. Androgen deficiency may also lead to the development of the bone disease related to CKD (with the higher incidence of bone fractures), anemia, decreased libido, impairment of sexual function and depression. Finally, the association of low plasma testosterone concentrations with worse outcomes in male hemodialysis patients has been recently described [5].

Testosterone therapy is not exempted from risks, therefore the evidence from large, clinical studies, suggesting benefits of such a treatment, are needed before it could be recommended in CKD patients with hypogonadism [4, 5].
Abnormalities of the hypothalamic-pituitary-gonadal axis in female CKD patients

Women with CKD also present a variety of derangements of the hypothalamic-pituitary-gonadal axis (Table 2). The consequences of which are anovulatory menstrual cycles and thus infertility.

Luteinizing hormone

In most premenopausal CKD patients serum LH concentration is increased. In healthy premenopausal females secretion of LH occurs in a pulsatile manner. In women with CKD, the disruption cyclic GnRH release in the hypothalamus leads to the loss of appropriate pulsatile release of LH by the pituitary. In healthy females, estradiol feedback blunts the magnitude of LH pulses, while in women with CKD, it fails to diminish the LH surge, what suggests the feedback is impaired. The aforementioned disturbances lead to the impairment of ovulation what is the direct cause of infertility in women with CKD [6].

Follicle-stimulating hormone

Conversely to the altered concentrations of serum LH, in the majority of premenopausal women with CKD, the serum concentrations of FSH are normal, thus the FSH/LH ratio is decreased. This phenomenon seem to contradict the assumption of primary ovarian failure in CKD and suggests that rather the hypothalamic–pituitary axis deregulation occurs [6].

Prolactin

In women on RRT the serum prolactin concentrations are most often increased and the surge of plasma prolactin after the thyrotropin-releasing hormone (TRH) administration is blunted. In this group of patients amenorrhea is most frequent in patients with high serum prolactin concentration [6].

Estrogens

In women with CKD, the serum concentrations of estradiol may be either normal, or low and are consistently lower if hyperprolactinemia occurs. In the second half of menstrual cycle, serum progesterone concentrations are decreased due to the defective follicle luteinization. The aforementioned hormonal disturbances are the consequence of derangements of regulation at the hypothalamus level [6].

One of the most important consequences of the low plasma estrogens concentration is bone disease [7]. Women with amenorrhea not only have decreased serum estrogens concentrations, but also lower mineral bone density in comparison with the regularly menstruating female dialysis patients. The results of small interventional studies suggest that treatment with transdermal estradiol, or treatment with a selective estrogen receptor modulator (SERM) – raloxifene may increase bone mineral density in postmenopausal females on hemodialysis. However it must be emphasized (especially in the light of the potential cardiovascular adverse effects), that currently long-term studies safety of hormone replacement, or SERM therapy in women with CKD are not available.

Abnormalities in the growth Hormone-insulin like growth factor (somatotropic) axis

Several hormones and growth factors are involved in the appropriate function of the somatotropic axis in human. The list of the most important comprises of e.g. growth hormone (GH), insulin-like growth factor 1 and 2 (IGF-1 and -2), IGF binding proteins (IGFBP) and the IGFBP proteases. Physiological function of the proteins mentioned above is the modulation of somatic growth and cellular proliferation.

The disruptions of the somatotropic axis have been reported in children, as well as in adults with CKD and may have substantial clinical consequences. In children the most severe is the growth retardation with decreased final adult height. It is of note, that growth impairment in patients with CKD is associated with increased morbidity and mortality [8, 9].

Growth hormone

Generally, in children and adult CKD patients, serum GH concentration is normal or elevated depending on the extent of the GFR impairment [10], what is caused by a reduction of the renal hormone’s clearance with the concomitant increase of GH secretion. Hyperglycemia induced by glucose infusion suppresses GH secretion in individuals with no kidney disease, but fails to do so in CKD patients. Moreover, in CKD the exaggerated GH secretion rate after the stimulation with exogenous GHRH occurs.

All of the alterations mentioned above have led to the theory of GH resistance or in-
sensitivity in patients with terminal CKD. This may be caused by the decreased density of GH receptors in the target organs, as the serum growth hormone binding protein (GHBP) concentration (which is a cleaved product of the GH receptor and may be used to assess GH receptor density in different organs) is decreased in children and adults with CKD proportionally to the decrease in glomerular filtration.

Additionally, evidences exist suggesting that in uremia GH resistance may be also post-receptor level with the alteration of intracellular signal transduction. This is due to the defect in the GH activated JAK2 and STAT signal transduction caused by the impaired phosphorylation and nuclear translocation of the cascade of STAT proteins [10]. Also the increased expression of suppressor of cytokine signaling (SOCS2 and SOCS3) genes may lead to the suppression in the GH signal transduction [12].

Among other factors contributing to the GH resistance in CKD: metabolic acidosis, inflammation and hyperparathyroidism can be reckoned.

Insulin-like growth factors

Contrary to the traditional views the influence of GH in the promotion of linear growth is not only caused by the GH related stimulation of IGF-1 synthesis in the liver, which then reaches the bones’ growth plate to stimulate growth. It has been recently shown that not all of the effects of GH are mediated by IGF-1.

IGF-1 and IGF-2 can be locally synthesized locally by most tissues, (including the bones’ growth plate). Nevertheless, liver slays the main source of circulating IGF-1.

The most of IGF-1 circulates in serum as a 150kDa complex with IGF Binding protein-3 (IGFBP3) and the acid labile subunit (ALS), although IGF-1 can also form complexes with other IGF-binding proteins (IGFBP-1 to 6).

Concentration of IGF-1 (the most important factor in the rapid growth during the puberty period) tends to be normal in pre-terminal kidney disease (CKD 1–4).

Serum free IGF-1 concentration decreases with the stages of CKD. In CKD 5 such a decrease is mostly due to the elevated concentrations of IGF-binding proteins -1, -2, -4, and -6 what results in the diminished pool of free IGF-1. Also, the decreased bioavailability of IGF-1 in the target organs as a result of increased proteolysis of IGFBP-3 has been reported.

Additionally, a small (1 kDa weight) IGF-1 inhibitor has been identified in the sera of patients with CKD, but the detailed structure of this particle has not yet been characterized.

Finally, the resistance to IGF-1 in CKD is also caused by the defect in intracellular signal transduction as both: the autophosphorylation of the IGF-1 receptor tyrosine kinase and susceptibility of the IGF-1R tyrosine kinase to the exogenous insulin receptor substrate-1 (IRS-1) are diminished in CKD [8, 9, 11, 12].

Serum concentration of IGF-2 is in the normal range in pre-terminal kidney disease and increased in CKD stage 5.

Growth hormone therapy

In spite of the normal or increased serum GH concentrations the aforementioned target organ resistance/insensitivity to GH gives the rationale for the exogenous recombinant human GH (rhGH) treatment children with growth retardation caused by CKD. Such treatment was found to be both efficacious and safe and resulted in a catch-up growth. 65% of children treated with rhGH may reach almost normal height in the adulthood [13]. The best response to rhGH treatment was found in patients in predialysis stages of CKD, probably due to better GH sensitivity [14]. The treatment with rhGH has been proven to be also effective in treatment of growth retardation (caused mainly by the glucocorticoid administration) in children after kidney transplantation.

Despite clear benefits (e.g. promoting muscle mass gain and decreasing the protein energy wasting [8, 9, 11, 12]) rhGH administration in adult CKD patients is not exempted from risks. Clinical studies proving the safety and efficacy of rhGH treatment in CKD patients need to be conducted, before the safe recommendation of such therapy in this group of patients.

Abnormalities in the thyroid gland and hypothalamic-pituitary-thyroid axis

Abnormalities in both the thyroid gland’s function and structure (increased volume of the thyroid gland and higher prevalence of goiter) are common in CKD patients [15]. Uremia affects the hypothalamus-pituitary-thyroid axis, as well as the peripheral metabolism of thyroid
hormones, thus serum concentrations of thyroid hormones are commonly not normal in CKD patients [15]. The differences in the thyroid hormones' profile alterations in CKD and primary hypothyroidism and chronic non-thyroid, non-kidney illness are presented in Table 3 [16].

### Table 2

**Hypothalamic–pituitary–thyroid axis alterations in chronic kidney disease, chronic nonthyroidal, nonkidney illness and primary hypothyroidism**

<table>
<thead>
<tr>
<th>Condition</th>
<th>TSH</th>
<th>T4</th>
<th>T3</th>
<th>rT3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic kidney disease</td>
<td>N</td>
<td>N↓</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>Chronic nonthyroidal, nonkidney illness</td>
<td>N</td>
<td>N↓</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>Primary hypothyroidism</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>N</td>
</tr>
</tbody>
</table>

N – normal; TSH – thyroid-stimulating hormone; T4 – thyroxin; T3 – triiodothyronine; rT3 – reverse triiodothyronine

**Thyroid hormones**

In patients with CKD the serum concentration of thyroxin (T4) is usually normal and serum triiodothyronine (T3) concentration may be either normal, or reduced. Low T3 syndrome is the most common disturbance in CKD patients, while subclinical hypothyroidism is the most common thyroid disorder found in this group of patients [17, 18].

The reduction of serum T3 concentration in CKD patients is a result of the impaired conversion of T4 to T3 caused by the of iodothyronine deiodinase as a result of malnutrition and/or chronic metabolic acidosis. Moreover, the decrease in peripheral conversion of T4 to T3 caused by the reduced clearance of inflammatory cytokines such as TNF-a and IL-6 has been described in CKD [17, 18].

Although T3 is the most active of thyroid hormones, CKD patients with low serum T3 concentrations usually appear clinically euthyroid, probably because the expression of messenger RNA for c-erb-A α and β T3 receptors in the mononuclear cells is increased.

In spite of the decreased renal clearance of rT3 serum concentrations of this hormone in CKD patients are normal. This is in contrast with chronic non-thyroid diseases and is probably caused by the increased cellular uptake of rT3 and also the redistribution of rT3 from the vascular to extravascular space and. Conversely, serum free-rT3 concentrations are elevated in CKD what is a result of reduced renal clearance.

Importantly the decreased concentrations of thyroid hormones, which are often seen in patients with CKD, may not necessarily be the indicator of thyroid dysfunction. These alterations may be a mere reflection of the chronic illness and/or malnutrition. Traditionally Low T3 status of CKD was viewed as an adaptation, promoting energy saving beneficial in the uremic wasting. Nonetheless, low serum T3 concentration in CKD patients is connected with the endothelial dysfunction, atherosclerosis and cardiac abnormalities. Moreover, low serum free-T3 has been linked with the increased cardiovascular mortality in hemodialysed patients [19].

Levothyroxine treatment is not exempted from risks (among them negative protein balance caused by the increased muscle catabolism). There is a need of further clinical studies with clear evidence of benefits of such a therapy in CKD subjects before levothyroxine supplementation can be recommended in these patients [18, 11].

**The thyroid-stimulating hormone**

Serum concentrations of thyroid-stimulating hormone (TSH) are usually normal in CKD patients even despite a tendency to low serum T4 and T3 concentrations. This discrepancy seems to suggest the deregulation of hypothalamic–pituitary–thyroid axis.

In CKD patients the pituitary receptor response to TRH is blunted what causes a decrease in the production of TSH. Moreover, the response in TSH release after stimulation with TRH is sluggish because of the impaired renal clearance and prolonged half-life of TSH. Also the normal daily rhythm of TSH release with a peak in the late evening or early morning is diminished and the nocturnal TSH surge is reduced [16, 18].
**Primary hypothyroidism and hyperthyroidism**

Increased prevalence of both overt and subclinical hypothyroidism in CKD patients has been described. Nonetheless, the diagnosis of hypothyroidism in this group of patients raises many significant difficulties because the typical signs and symptoms of hypothyroidism, such as hypothermia, pallor, and asthenia, are also common in the clinical picture of advanced CKD. This is why the diagnosis of primary hypothyroidism in patients with CKD should only be considered if the coexistence of elevated serum TSH concentration and clearly low serum T4 concentrations occurs.

CKD is associated with the decreased iodide excretion, what causes the elevation of serum inorganic iodide content and the increased content of iodide in the thyroid gland. The former causes enlargement of the thyroid gland and contributes to the increased prevalence of goiter in CKD. Additionally, the excess of iodide in the thyroid gland may contribute to hypothyroidism through the prolonged Wolff-Chaikoff effect.

In chronic hemodialysis patients a transient increase of serum T4 concentration, caused by using heparin as an anticoagulant, occurs. Heparin competes with T4 at the binding site of the hormone-binding protein, what leads to an increase of serum T4 concentrations for at least 24 hours, thus the blood samples for the assessment of serum thyroid hormones concentration should be collected before heparin administration, which is before the dialysis session.

Among the clinical consequences of hypothyroidism in CKD anemia, muscle wasting, and depression can be reckoned. It is of note that the decreased concentrations of T3 are the independent predictor of cardiovascular and all-cause mortality in patients with CKD [16, 20].

The prevalence of hyperthyroidism in CKD patients is similar as in the general population. Nevertheless it should be remembered that some aspects of hyperparathyroidism can indeed accelerate the progression of CKD i.e. increased renal blood flow that causes the increase of filtration pressure with glomerular hyperfiltration and increased free radicals generation (caused by the decreased activity of superoxide dismutase). 

**Abnormalities in insulin and glucagon**

Diverse alterations in the insulin-glucose environment are seen in patients with CKD what contributes to the disrupted carbohydrate metabolism [22, 23].

**Insulin secretion and clearance**

Insulin secretion is impaired in CKD what is caused by, among others, high serum PTH and low serum plasma 1,25(OH)2D3 concentrations.

The kidney is an important organ in the insulin metabolism. Insulin is filtered in the glomeruli and then reabsorbed in the proximal tubule. In apparently healthy subjects renal clearance of insulin is roughly 200 mL/minute what exceeds the glomerular filtration rate (GFR), indicating also peritubular uptake of insulin takes place. It is estimated that 6-8 units of insulin are removed daily by the kidney, what is 25-40% of the total removal of endogenous insulin. CKD patients develop a decrease in the metabolic clearance of insulin when GFR falls below 40 ml/minute. This causes fasting hyperinsulinemia and accounts for decreased insulin requirement in diabetic patients with CKD [22].

**Insulin Resistance**

Peripheral resistance to insulin is seen early in the course of CKD. Mostly the skeletal muscles develop decreased insulin sensitivity and higher serum insulin concentrations are required to increase glucose uptake by skeletal muscle. It needs to be stressed that the defect does not only concern the insulin receptor, but presumably also takes place at the postreceptor level, as the impairment of phosphatidylinositol 3-kinase activity (PI3-K) was documented in CKD patients.

As it was mentioned above insulin resistance occurs early in CKD and tends to aggravate with the CKD stages. It is thus found in the majority of patients with advanced CKD. After initiating RRT peripheral insulin resistance markedly decreases, however only after several weeks of treatment. Presumably, an unidentified dialyzable uremic "toxins" are involved in the pathogenesis of improper insulin activity in target organs. Such compounds with a molecular weight of 1 to 2 kDa are specific for CKD – they are not found in nonuremic patients with insulin resistance.

Some of the factors involved in insulin resistance in CKD are generally modifiable.
For example in HD patients, insulin resistance is ameliorated by treatment with erythropoietin or 1,25(OH)₂D₃ and in predialysis patients can be ameliorated by dietary protein restriction.

Also the serum concentrations of insulin antagonists: glucagon and growth hormone are frequently increased in CKD patients. It has been postulated that these two hormones, as well as metabolic acidosis, chronic inflammation and increased activity of renin-angiotensin system activity may also participate in the pathogenesis of insulin resistance in CKD patients [23].

**Clinical consequences of hyperglycemia and insulin resistance**

Both the hyperglycemia and insulin resistance in patients with CKD have been shown to increase cardiovascular risk and CKD progression and contribute to the development of hypertension due to the higher salt sensitivity cause by the increased tubular sodium reabsorption. Insulin resistance may also participate in the development of malnutrition often found in this group of patients and as it stimulates the muscle catabolism through the activation of a common proteolytic pathway via the ubiquitin–proteasome system [22, 23].

**Abnormalities in the hormones of adipose tissue**

The adipose tissue can be perceived as an endocrine organ as it produces a variety of biologically active substances (adipokines). The increase of plasma concentrations of different adipokines are found in CKD patients. The most important adipokines, of proven systemic activity are among others: leptin adiponectin, resistin and visfatin [24].

Plasma leptin concentration is increased in patients with CKD as its clearance is decreased in the failing kidney. Leptin is a factor stimulating the proliferation and differentiation of hematopoietic stem cells. It is likely that the effects of leptin and erythropoietin are synergistic. Furthermore, hyperleptinemia stimulates the activity of the sympathetic nervous system and is therefore involved in the in progression of CKD, pathogenesis of hypertension and cardiovascular diseases [24].

Plasma concentration of adiponectin is also elevated in patients with CKD what is caused by the disturbances of its biodegradation and elimination by the failing kidneys. Clinical consequences of increased plasma adiponectin concentration in CKD are not clear [24]. Nonetheless it seems that in CKD patients the unique anti-atherosclerotic activity of adiponectin is diminished due to the resistance at a receptor level.

Plasma concentration of resistin is increased in CKD patients, mainly due to its reduced renal clearance. Resistin, at concentrations typical for CKD patients inhibits neutrophil activity. It may thus be one of prominent causes of the increased prevalence of infections in CKD patients. Moreover, resistin appears to have a role in the pathogenesis of cardiovascular disease in CKD patients as chronic hemodialysis patients with low serum resistin concentration are characterized by a poor hospitalization-free survival [24].

Plasma concentration of visfatin gradually increases with the decrease of GFR and is positively correlated with endothelial dysfunction. This adipokine stimulates monocyte adhesion to the endothelial cells. Visfatin also may be involved in the pathogenesis of malnutrition in CKD. Additionally, high plasma visfatin concentration predicted mortality in CKD patients [24].

**REFERENCES**

8. Mak RH, Cheung WW, Roberts CT Jr. The growth hormone-insulin-like growth factor-I axis in chronic